Evotec AG and Roche to Develop EVT 101 for Treatment-Resistant Depression; Deal Valued at More Than $300 Million

HAMBURG, Germany and BASEL, Switzerland, March 9, 2009 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (Nasdaq:EVTC) and Roche (SWX: RO, ROG; OTCQX: RHHBY) announced today that they have entered into an agreement for Phase II clinical development of EVT 101 in patients with treatment-resistant depression. The potential value of this transaction exceeds USD 300 million.